Enrollment snafus implicated in psychiatric drug trials; FDA gives orphan nod to Xoma;

Conversations on Twitter :

  • "Is there an app for that?" Thought-provoking post & discussion on how oncologists sort through new anticancer drugs.
  • Aging fathers & rising mutations: Nature paper sparks discussion ranging from Hugh Hefner's offspring to schizophrenia prevalence.

 @FierceBiotech: From FierceCRO: Researchers bristle at India's proposed trial reforms. Story | Follow @FierceBiotech

 @JohnCFierce: Fate Therapeutics raised a bit more than $9M for their stem cell work. Run by biotech vet Bill Rastetter. More | Follow @JohnCFierce

 @RyanMFierce: J&J is heading into Phase III with a new RA drug, add on big inflammation biz, not sure what hopes are for this one. More | Follow @RyanMFierce

> Are trials for psychiatric drugs enrolling the wrong patients? Report

> The CEO of the biotech company Tigenix sounded upbeat about the prospects of nailing down a partner for CX601 by the end of the year. Story

> The Oregon Translational Research and Development in Portland faces a major decision next month when state offices make a call on providing $2 million to help keep the organization vital in driving biotech growth in the region. More

> The FDA awarded the biotech Xoma orphan drug status for its lead drug candidate gevokizumab for treating an eye ailment called uveitis. Article

> Samsung, known widely for its consumer electronics, has jumped into the genome analysis game. Item

> EU inspectors green-lighted Alexza's plan after the FDA raised concerns about the facility. Article

Pharma News

 @FiercePharma: Thumbs up from HSBC on India's pharma sector. Dr Reddy's, Sun Pharma, Cipla are its faves--Reuters. | Follow @FiercePharma

> FDA bears greater ethical burden in post-marketing trials, NEJM says. Article

> Indian sales reps strike to demand strict drug-promo rules. More

> AZ's Nexium tops Q2 sales ranks, with BMS' Abilify on its heels. Report

> Pfizer, Mylan plan joint attack on Japanese generics market. Story

Medical Device News

@FierceMedDev: The FBI arrested two former ArthoCare execs, charging them with defrauding investors of $400M. Release | Follow @FierceMedDev

 @MarkHFierce: Faridabad in India is becoming a huge hub for medical device and equipment manufacturers. More | Follow @MarkHFierce

 @DamianFierce: CareFusion's fourth Class I recall of the summer deals with is Alaris infusion pumps. Article | Follow @DamianFierce

> Varian Medical chooses South Korea for overseas subsidiary. News

> Devicemakers cautiously optimistic after meeting with FDA chief. Story

> GI Dynamics gains FDA nod for obesity device pivotal trial. Item

> CareFusion hit with another Class I recall over pump. News

Vaccines News

> Bavarian Nordic in peril if U.S. nixes smallpox vaccine order. Report

> Labs, NIH zero in on painless vaccine technology. More

> NIAID provides $7.8M in grants for HIV research. Article

> PATH Malaria Vaccine Initiative creates reference lab. Item

> Merck's Varivax slashes U.S. chickenpox cases. Story

Pharma Manufacturing News

> India's Faridabad builds manufacturing mass. Story

> EU inspectors give Alexza plant the approval that FDA denied it. News

> West tapping growth in India, Asia. More

> Forfeiture of 27 ANDAs is a small piece of Ranbaxy penalties. Item

And Finally… Researchers used DNA sequencing in a battle to thwart a killer strain of the bug Klebsiella pneumonia in an NIH hospital. Article (sub. req.)

Suggested Articles

Passage Bio filed to raise $125 million in its IPO. Now, it has outraised that goal by $91 million with a $216 million Wall Street debut.

The ruling reflects the judge’s belief that the FDA’s interpretation of the law on clinical trial reporting “is unlawful and must be set aside.”

Trutino will apply a platform designed to yield safer, more effective cytokines to the discovery of three oncology drugs for Boehringer.